<DOC>
	<DOCNO>NCT00376311</DOCNO>
	<brief_summary>To assess safety , tolerability clinical efficacy oral salmon calcitonin patient suffer osteoarthritis</brief_summary>
	<brief_title>Effects Oral Salmon Calcitonin Human Osteoarthritis</brief_title>
	<detailed_description>Osteoarthritis ( OA ) difficult condition manage , thus far , simple , effective intervention common cause pain disability . Because parenteral salmon calcitonin ( sCT ) positive effect canine experimental OA , phase IIa , randomize , placebo-controlled , double-blind trial evaluates safety , tolerance clinical efficacy oral formulation sCT patient OA . Patients receive tablet contain either placebo , 0.5 mg sCT 1 mg sCT take every day morning 15 minute breakfast 3 month .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>radiographic OA accord criterion American College Rheumatology ; morning joint stiffness 15 30 minute ; pain weight bear motion report great 40 mm 0100 mm visual analogue scale ; normal liver kidney function test ; serum CRP level &lt; 10 mg/l previous ongoing treatment antiresorptive drug bisphosphonates , estrogen raloxifene crystal deposition disease know hereditary congenital defect clinically significant hepatic , renal , cardiovascular , psychiatric , endocrine and/or hematological disease intraarticular injection either corticosteroid ( previous 3 month ) hyaluronan ( previous 6 month )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>Lequesne 's algo-functional score</keyword>
	<keyword>Biomarkers joint metabolism</keyword>
</DOC>